Articles from Align Technology, Inc.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that Patrick Mahomes, quarterback for the National Football League’s (NFL) Kansas City Chiefs, has joined the Invisalign Smile Squad as an ambassador for the brand. As part of the multi-year agreement, Patrick will share his Invisalign treatment experience with fans in a multi-channel campaign.

Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report fourth quarter and 2024 financial results on Wednesday, February 5, 2025, after the close of market. Financial results will be released at 4:00 p.m. ET (2:00 p.m. MT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it has received CE Mark in Europe under the Medical Device Regulation (MDR 2017/745) for Align’s Invisalign® Palatal Expander System. The Invisalign Palatal Expander System has also completed registration with MHRA for the United Kingdom and overseas territories.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights from the 2024 Invisalign Ortho Summit, Align’s premier clinical education and peer-to-peer networking experience designed to help doctors transform and grow their practice with Invisalign® clear aligners, iTero scanners, and the Align™ Digital Platform.

Align Technology, Inc. (NASDAQALGN) today announced the opening of its 2025 Annual Research Award Program to support clinical and scientific dental research in universities across the globe. This year, up to $300,000 will be awarded to university faculty for scientific and technological research initiatives to advance patient care in the fields of orthodontics and dentistry. Align Technology’s Research Award Program has funded approximately $3.75 million in research since the program’s inception in 2010.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at the following upcoming financial conferences. The presentations, as noted below, will be webcast live via the Investor Relations section of Align Technology's website at http://investor.aligntech.com. An archived replay will remain on the website for approximately three months.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it is planning to repurchase $275 million of Align’s common stock through open market repurchases under Align’s $1.0 billion stock repurchase program that was approved by Align's Board of Directors in January 2023.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced Frank Quinn, formerly Align vice president and general manager of the United States, will rejoin the company as executive vice president and managing director of the Americas region, reporting to Joe Hogan, Align president and CEO. As part of the global organizational restructuring plan that the company announced separately today, Raj Pudipeddi’s position as executive vice president and managing director of the Americas region and chief marketing officer has been eliminated and he will leave Align in the fourth quarter of 2024.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the third quarter ("Q3'24"). Q3'24 total revenues were $977.9 million, down 4.9% sequentially and up 1.8% year-over-year. Q3'24 total revenues were not significantly impacted by foreign exchange sequentially and unfavorably impacted by approximately $14.6 million or 1.5% year-over-year.(1) Q3'24 Clear Aligner revenues were $786.8 million, down 5.4% sequentially and down 1.0% year-over-year. Q3'24 Clear Aligner revenues were not significantly impacted by foreign exchange sequentially, and unfavorably impacted by approximately $11.7 million or 1.5% year-over-year.(1) Q3'24 Clear Aligner volume was down 4.0% sequentially and up 2.5% year-over-year. Q3'24 Imaging Systems and CAD/CAM Services revenues were $191.0 million, down 2.9% sequentially and up 15.6% year-over-year. Q3'24 Imaging Systems and CAD/CAM Services revenues were not significantly impacted by foreign exchange sequentially and unfavorably impacted by approximately $2.9 million or 1.5% year-over-year.(1)

Align Technology, Inc. (NASDAQALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced iTero intraoral scanner product innovations that provide a versatile overall solution for general practitioner (“GP”) dentists.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for restorative dentistry, today announced the release of the next innovation of Invisalign Smile Architect software, now with Multiple Treatment Plans allowing doctors to visually compare and modify orthodontic only and ortho restorative treatment plans side-by-side. The Multiple Treatment Plans are integrated into ClinCheck® treatment planning software for doctors to visually compare, review, and choose the best treatment option for each patient.

Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report third quarter 2024 financial results on Wednesday, October 23, 2024, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the U.S. District Court for the Northern District of California has granted preliminary approval of a settlement to resolve shareholder derivative litigation that has been pending since 2019. Under the terms of the settlement, plaintiffs will dismiss the lawsuits and release their claims. Align and the defendants deny any wrongdoing and are not making any monetary payments, other than a potential award of $575,000 in attorney’s fees to plaintiffs’ counsel, covered by insurance. A notice approved by the court regarding the settlement is attached.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at an upcoming financial conference. The presentation, as noted below, will be webcast live via the Investor Relations section of Align Technology's website at http://investor.aligntech.com. An archived replay will remain on the website for approximately three months.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced leadership updates for the Asia Pacific, Americas, and EMEA regions. Medical technology industry executive David Carr has joined Align as EVP and MD of the Asia Pacific region. Raj Pudipeddi, currently EVP and MD of the Asia Pacific region and Chief Marketing Officer (CMO) for Align, has assumed responsibility for the Americas region as EVP, while maintaining his responsibilities as CMO. Mr. Pudipeddi will continue to manage the APAC region through the end of the third quarter and support Mr. Carr as he onboards into the Company. Simon Beard will continue to lead the EMEA region as EVP and MD.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for restorative dentistry, today announced it is piloting a new U.S. Invisalign treatment promotional program for Costco members on Costco.com.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the second quarter ("Q2'24"). Q2'24 total revenues were $1,028.5 million, up 3.1% sequentially and up 2.6% year-over-year. Q2'24 total revenues were unfavorably impacted by foreign exchange of approximately $11.6 million or 1.1% sequentially and unfavorably impacted by approximately $18.1 million or 1.7% year-over-year.(1) Q2'24 Clear Aligner revenues were $831.7 million, up 1.8% sequentially and down 0.1% year-over-year. Q2'24 Clear Aligner revenues were unfavorably impacted by foreign exchange of approximately $9.5 million or 1.1% sequentially and unfavorably impacted by approximately $14.7 million or 1.7% year-over-year.(1) Q2'24 Clear Aligner volume was up 6.2% sequentially and up 3.2% year-over-year. Q2'24 Imaging Systems and CAD/CAM Services revenues were $196.8 million, up 9.2% sequentially and up 16.1% year-over-year. Q2'24 Imaging Systems and CAD/CAM Services revenues were unfavorably impacted by foreign exchange of approximately $2.1 million or 1.0% sequentially and unfavorably impacted by approximately $3.4 million or 1.7% year-over-year.(1)

Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for restorative dentistry, today introduced the iTero™ Design Suite, offering doctors an intuitive way to facilitate designs for 3D printing of models, bite splints, and restorations in-practice.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report second quarter 2024 financial results on Wednesday, July 24, 2024, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the award of twelve research grants to universities under the company’s fourteenth Annual Research Award Program.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced it has appointed Emory Wright, executive vice president, direct fabrication manufacturing platform, effective immediately. Mr. Wright will transition his current responsibilities for global operations, including treatment planning, and focus on scaling Align’s next generation direct fabrication manufacturing platform, working in close collaboration with Srini Kaza, who was promoted to executive vice president, research and development. Dr. Mitra Derakhshan, senior vice president, global clinical will assume responsibility for global treatment planning in the newly created role of executive vice president, chief clinical officer, global treatment planning and clinical services. Jitse Marree, vice president, global aligner manufacturing will continue to lead global clear aligner manufacturing operations and assume responsibility for Mr. Wright’s remaining global operations functions.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at upcoming financial conferences. The presentations, as noted below, will be webcast live via the Investor Relations section of Align Technology's website at http://investor.aligntech.com. An archived replay will remain on the website for approximately three months.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it is planning to repurchase $150 million of Align’s common stock through open market repurchases under Align’s $1.0 billion stock repurchase program that was approved by Align’s Board of Directors in January 2023.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the first quarter ("Q1'24"). Q1'24 total revenues were $997.4 million, up 4.3% sequentially and up 5.8% year-over-year. Q1'24 Clear Aligner revenues were $817.3 million, up 4.5% sequentially and up 3.5% year-over-year. Q1'24 Clear Aligner volume was up 2.1% sequentially and up 2.4% year-over-year. Q1'24 Imaging Systems and CAD/CAM Services revenues were $180.2 million, up 3.1% sequentially and up 17.5% year-over-year. Q1'24 Clear Aligner revenues were favorably impacted by foreign exchange of approximately $8.4 million or 1.0% sequentially and unfavorably impacted by approximately $3.9 million or 0.5% year-over-year.(1) Q1'24 Imaging Systems and CAD/CAM Services revenues were favorably impacted by foreign exchange of approximately $1.5 million or 0.9% sequentially and unfavorably impacted by approximately $0.9 million or 0.5% year-over-year.(1)

Align Technology, Inc. (NASDAQALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the “Better Way” new advertising campaign for the Invisalign brand featuring the “Invis is for Kids” tagline and hashtag.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that Align's Invisalign Palatal Expander System* has been included in the Australian Register of Therapeutic Goods (ARTG) and the New Zealand Web Assisted Notification of Devices Database (WAND), and is commercially available in both Australia and New Zealand. The ARTG and WAND entries for Invisalign Palatal Expender System cover broad patient applicability, including growing children, teens and adults (with surgery or other techniques).

Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report first quarter 2024 financial results on Wednesday, April 24, 2024, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that on Wednesday, February 21, 2024, the U.S. District Court for the Northern District of California granted summary judgment in favor of Align Technology, Inc. in two U.S. antitrust class action lawsuits (Simon & Simon, PC et al. v. Align Technology, Inc. and Snow et al. v. Align Technology, Inc.), filed initially in 2020 and 2021, respectively. These lawsuits challenged Align’s decision to end scan acceptance in the U.S. from a third-party scanner that was infringing Align’s intellectual property.

Align Technology, Inc. (NASDAQALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that for the first time, Align Technology is included in the Intellectual Property Owners Association annual report of the top 300 organizations granted U.S. patents. For 2023, Align is at position #270, with 158 U.S. patents granted, a 36% increase compared to 2022.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the fourth quarter ("Q4'23") and year ended December 31, 2023 ("2023"). Q4'23 total revenues were $956.7 million, down 0.4% sequentially and up 6.1% year-over-year. Q4'23 Clear Aligner revenues were $781.9 million, down 1.6% sequentially and up 6.9% year-over-year. Q4'23 Clear Aligner volume was down 1.6% sequentially and down 0.6% year-over-year. Q4'23 Imaging Systems and CAD/CAM Services revenues were $174.8 million, up 5.8% sequentially and up 2.9% year-over-year. Q4’23 Clear Aligner revenues were unfavorably impacted by foreign exchange of approximately $10.7 million or 1.4% sequentially and favorably impacted by approximately $12.0 million or 1.6% year over year.(5) Q4'23 Imaging Systems and CAD/CAM Services revenues were unfavorably impacted by foreign exchange of approximately $2.1 million or 1.2% sequentially and favorably impacted by approximately $1.9 million or 1.1% year over year.(5) Q4'23 operating income was $171.5 million resulting in an operating margin of 17.9%. Q4'23 operating margin was unfavorably impacted by foreign exchange of approximately 0.6 points sequentially and favorably impacted by approximately 0.6 points year over year.(5) Q4'23 net income was $124.0 million, or $1.64 per diluted share. On a non-GAAP basis, Q4'23 net income was $183.5 million, or $2.42 per diluted share.

Align Technology, Inc. (NASDAQALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the launch of the iTero Lumina™ intraoral scanner – with a 3X wider field of capture in a 50% smaller and 45% lighter wand, delivering faster scanning speed, higher accuracy, superior visualization, and a more comfortable6 scanning experience.

Align Technology, Inc. (Align) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it has completed the acquisition of privately-held Cubicure GmbH, a pioneer in direct 3D printing solutions for polymer additive manufacturing that develops, produces, and distributes innovative materials, equipment, and processes for novel 3D printing solutions.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report fourth quarter and 2023 financial results on Wednesday, January 31, 2024, after the close of market. Financial results will be released at 4:00 p.m. ET (2:00 p.m. MT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the U.S. Food and Drug Administration (FDA) has cleared Align’s Invisalign® Palatal Expander System* for commercial availability in the U.S. The FDA 510(k) clearance is for broad patient applicability, including growing children, teens, and adults (with surgery or other techniques).

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that Health Canada issued an updated medical device license to Align for its Invisalign® Palatal Expander System*. The updated license is for broad patient applicability, including growing children, teens, and adults (with surgery or other techniques). The Invisalign Palatal Expander System is available on a limited basis in Canada.

Align Technology, Inc. (NASDAQALGN) today announced that its Board of Directors has appointed Mojdeh Poul, former EVP and Group President of 3M Health Care, and Kevin Conroy, President, Chief Executive Officer, and Chairman of the Board of Exact Sciences.

Align Technology, Inc. (NASDAQALGN) today announced the opening of its 2024 Annual Research Award Program to support clinical and scientific dental research in universities across the globe. This year, up to $300,000 will be awarded to university faculty for scientific and technological research initiatives to advance patient care in the fields of orthodontics and dentistry. Align Technology’s Research Award Program has funded approximately $3 million in research since the program’s inception in 2010.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it is planning to repurchase $100 million of Align’s common stock through open market repurchases under Align’s $1.0 billion stock repurchase program that was approved by Align's Board of Directors in January 2023. This $100 million open market repurchase is in addition to the $250 repurchase of Align's common stock under an accelerated stock repurchase agreement that was announced on October 27, 2023.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at the following upcoming financial conferences. The presentations, as noted below, will be webcast live via the Investor Relations section of Align Technology's website at http://investor.aligntech.com. An archived replay will remain on the website for approximately three months.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it has entered into a new accelerated stock repurchase agreement ("ASR") with Citibank, N.A. (“Citi”), to repurchase $250 million of Align's common stock under Align’s $1.0 billion stock repurchase program that was approved by Align's Board of Directors in January 2023.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the third quarter ("Q3'23"). Q3'23 total revenues were $960.2 million, down 4.2% sequentially and up 7.8% year-over-year. Q3'23 Clear Aligner revenues were $794.9 million, down 4.5% sequentially and up 8.5% year-over-year. Q3'23 Clear Aligner volume was down 3.3% sequentially and up 2.3% year-over-year. Q3'23 Imaging Systems and CAD/CAM Services revenues were $165.3 million, down 2.5% sequentially and up 4.9% year-over-year. Q3’23 Clear Aligner revenues were unfavorably impacted by foreign exchange of approximately $2.0 million or 0.3% sequentially and favorably impacted by approximately $3.8 million or 0.5% year-over-year.(1) Q3'23 Imaging Systems and CAD/CAM Services revenues were unfavorably impacted by foreign exchange of approximately $0.7 million or 0.4% sequentially and favorably impacted by approximately $0.4 million or 0.3% year-over-year.(1)

Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report third quarter 2023 financial results on Wednesday, October 25, 2023, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights from the 2023 Invisalign GP Summit, the Company’s premier clinical education and networking experience designed to help doctors transform and grow their practice with Invisalign® clear aligners, iTero scanners, and the Align Digital Platform™. Over the course of three days, more than 1,000 doctors and practice team members from across North America came together, alongside Align and peer-to-peer speakers to share treatment and workflow best practices, hands-on experiences to sharpen clinical skills, and practice growth and marketing strategies.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today introduced the Invisalign® Palatal Expander System,* a modern and innovative direct 3D printed device based on a proprietary and patented technology. Invisalign Palatal Expanders are intended for use in rapid expansion and subsequent holding of skeletal and/or dental narrow maxilla (upper jaw) with primary, mixed, or permanent dentition during treatment of growing patients. The Invisalign Palatal Expander is Align’s first direct 3D printed orthodontic device and provides a safe, comfortable, and clinically effective** alternative to metal palatal expanders that require manually turning a screw in the device in the mouth daily to achieve expansion.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today introduced a new doctor enabled direct ship to patient feature in its Vivera™ Retainer Subscription (VRS) platform that allows doctors to have subsequent retainers sent directly to their patients in order to meet their ongoing long-term retention needs. The VRS platform is part of Align’s broader Doctor Subscription Program (DSP) introduced to doctors in the United States and Canada in 2021.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today introduced new software innovations to accelerate digital practice transformation.

Align Technology, Inc. (Align) (Nasdaq: ALGN) today announced that it has entered into a definitive agreement to acquire privately held Cubicure GmbH, a pioneer in direct 3D printing solutions for polymer additive manufacturing that develops, produces, and distributes innovative materials, equipment, and processes for novel 3D printing solutions. Cubicure’s patented Hot Lithography technology uses a special heating and coating mechanism that enables the processing of highly viscous resins to produce particularly tough and temperature-resistant polymers. This high precision 3D printing process facilitates the unprecedented additive manufacturing of resilient components with an astonishing first of its kind material quality performance.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today introduced Plan Editor in ClinCheck® treatment planning software, a new tool in the Align digital workflow built into the Align Digital Platform™.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today introduced a new SmartForce feature, attachment-free aligner activation, that helps minimize the number of attachments while maintaining predictable treatment outcomes. The new SmartForce attachment-free aligner activation feature builds on Align’s foundational biomechanics for clear aligners and its database of more than 15.7 million Invisalign patients to optimize tooth movements. It is the latest of the company’s many biomechanical innovations that enhance experiences for patients in Invisalign treatment.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the opening of its customer education and training center in Toronto, Canada to promote professional engagement and training about Invisalign clear aligners, iTero scanners and the Align Digital Platform™ for Align customers.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that on August 21, 2023, the Superior Court, State of California, County of Santa Clara issued an order granting Align’s petition to confirm and denying SmileDirectClub LLC (“SDC”) petition to vacate a $63 million arbitration award entered in favor of Align.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the second quarter ("Q2'23"). Q2'23 total revenues were $1,002.2 million, up 6.3% sequentially and up 3.4% year-over-year. Q2'23 Clear Aligner revenues were $832.7 million, up 5.4% sequentially and up 4.3% year-over-year. Q2'23 Clear Aligner volume was up 5.0% sequentially and up 0.9% year-over-year. Q2'23 Imaging Systems and CAD/CAM Services revenues were $169.5 million, up 10.5% sequentially and down 1.0% year-over-year. Q2’23 Clear Aligner revenues were favorably impacted by foreign exchange of approximately $1.2 million or 0.1% sequentially and unfavorably impacted by approximately $16.3 million or 1.9% year-over-year.(1) Q2'23 Imaging Systems and CAD/CAM Services revenues were favorably impacted by foreign exchange of approximately $0.1 million or 0.1% sequentially and unfavorably impacted by approximately $3.1 million or 1.8% year-over-year.(1) Q2'23 operating income was $171.9 million resulting in an operating margin of 17.2%. Q2'23 operating margin was unfavorably impacted by foreign exchange by approximately 1.1 points year-over-year.(1) Q2'23 net income was $111.8 million, or $1.46 per diluted share. On a non-GAAP basis, Q2'23 net income was $170.4 million, or $2.22 per diluted share.

Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report second quarter 2023 financial results on Wednesday, July 26, 2023, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, announced today that the company will host an in-person Investor Day on Wednesday, September 6, 2023, beginning at 1:00 p.m. Pacific Time.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the award of eleven research grants to universities under the company’s thirteenth Annual Research Award Program.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at upcoming financial conferences. The presentations, as noted below, will be webcast live via the Investor Relations section of Align Technology's website at http://investor.aligntech.com. An archived replay will remain on the website for approximately three months.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at the following upcoming financial conference. The presentation, as noted below, will be webcast live via the Investor Relations section of Align Technology's website at http://investor.aligntech.com. An archived replay will remain on the website for approximately three months.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the first quarter ("Q1'23"). Q1'23 total revenues were $943.1 million, up 4.6% sequentially and down 3.1% year-over-year. Q1'23 Clear Aligner revenues were $789.8 million, up 7.9% sequentially and down 2.5% year-over-year. Q1'23 Clear Aligner volume was down 1.4% sequentially and down 3.9% year-over-year. Q1'23 Imaging Systems and CAD/CAM Services revenues were $153.3 million, down 9.7% sequentially and down 6.2% year-over-year. Q1’23 Clear Aligner revenues were favorably impacted by foreign exchange of approximately $21.8 million or 2.8% sequentially and unfavorably impacted by approximately $29.1 million or 3.6% year over year.(1) Q1'23 Imaging Systems and CAD/CAM Services revenues were favorably impacted by foreign exchange of approximately $4.0 million or 2.7% sequentially and unfavorably impacted by approximately $5.8 million or 3.6% year over year.(1) Q1'23 operating income was $133.5 million resulting in an operating margin of 14.2%. Q1'23 operating margin was favorably impacted by foreign exchange of approximately 1.5 points sequentially and unfavorably impacted by approximately 2.0 points year over year.(1) Q1'23 net income was $87.8 million, or $1.14 per diluted share. On a non-GAAP basis, Q1'23 net income was $140.6 million, or $1.82 per diluted share.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that Align Technology has been honored as a “Technology Partner of the Year” by Junior Achievement of Northern California (JA NorCal) at the Junior Achievement of Northern California 2023 Business Hall of Fame celebration event held in San Francisco. Julie Paulsen, Align Technology vice president, Corporate Social Responsibility, was nominated as a 2023 “Junior Achievement of Northern California Volunteer of the Year,” chosen along with 11 other volunteers from among 1,000 volunteers.

Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report first quarter 2023 financial results on Wednesday, April 26, 2023, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that after nearly six years with Align, Yuval Shaked, executive vice president and managing director of iTero scanner and services, has decided to leave the company for personal reasons and spend more time with his family. He will remain with Align and continue as a member of Align Technology President and CEO Joe Hogan’s staff supporting strategic initiatives and programs through 2023. Mr. Shaked will transition his role to Karim Boussebaa, who will join Align on February 27 and assume the role of executive vice president and managing director of iTero scanner and services, effective immediately.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it has entered into a new accelerated stock repurchase agreement ("ASR") with Citibank, N.A. (“Citi”), to repurchase $250 million of Align's common stock under Align’s $1.0 billion stock repurchase program announced on May 13, 2021.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the fourth quarter ("Q4'22") and year ended December 31, 2022 ("2022"). Q4'22 total revenues were $901.5 million, up 1.3% sequentially and down 12.6% year-over-year. Q4'22 Clear Aligner revenues were $731.7 million, flat sequentially and down 10.3% year-over-year. Q4'22 Clear Aligner volume was up 1.1% sequentially and down 7.5% year-over-year. Q4'22 Imaging Systems and CAD/CAM Services revenues were $169.9 million, up 7.8% sequentially and down 21.3% year-over-year. Q4’22 Clear Aligner revenues were unfavorably impacted by foreign exchange of approximately $13.4 million or 1.8% sequentially and approximately $56.4 million or 7.2% year over year.(1) Q4'22 Imaging Systems and CAD/CAM Services revenues were unfavorably impacted by foreign exchange of approximately $2.7 million or 1.5% sequentially and approximately $11.2 million or 6.2% year over year.(1) Q4'22 operating income was $112.7 million resulting in an operating margin of 12.5%. Q4'22 operating margin was unfavorably impacted by foreign exchange of approximately 0.9 points sequentially and approximately 4.2 points year over year.(1) Q4'22 net income was $41.8 million, or $0.54 per diluted share. On a non-GAAP basis, Q4'22 net income was $134.2 million, or $1.73 per diluted share. (3)

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report fourth quarter and 2022 financial results on Wednesday, February 1, 2023, after the close of market. Financial results will be released at 4:00 p.m. ET (2:00 p.m. MT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com.

Align Technology, Inc. (NASDAQALGN) today announced the opening of its 2023 Research Award Program to support clinical and scientific dental research in universities across the globe. This year, up to $300,000 will be awarded to university faculty for scientific and technological research initiatives to advance patient care in the fields of orthodontics and dentistry. Align Technology’s Research Award Program has funded approximately $2.7 million in research since the program’s inception in 2010.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it has entered into a new accelerated stock repurchase agreement ("ASR") with Goldman Sachs & Co. LLC, to repurchase $200 million of Align's common stock under Align’s $1.0 billion stock repurchase program announced on May 13, 2021. In addition to the ASR, Joe Hogan, president and CEO, intends to personally purchase $2.0 million of Align’s common stock, in addition to his $2.0 million purchase in May 2022.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the third quarter of fiscal 2022 ("Q3'22"). Q3'22 total revenues were $890.3 million, down 8.2% sequentially and down 12.4% year-over-year. Q3'22 Clear Aligner revenues were $732.8 million, down 8.2% sequentially and down 12.5% year-over-year. Q3'22 Clear Aligner volume was down 3.6% sequentially and down 11.9% year-over-year. Q3'22 Imaging Systems and CAD/CAM Services revenues were $157.5 million, down 8.0% sequentially and down 11.7% year-over-year. Q3’22 Clear Aligner revenues were unfavorably impacted by foreign exchange of approximately $21.0 million or 2.8% sequentially and approximately $47.4 million or 6.1% year over year.(1) Q3'22 Imaging Systems and CAD/CAM Services revenues were unfavorably impacted by foreign exchange of approximately $4.1 million or 2.5% sequentially and approximately $9.9 million or 5.9% year over year.(1) Q3'22 operating income was $143.7 million resulting in an operating margin of 16.1%. Q3'22 net income was $72.7 million, or $0.93 per diluted share. On a non-GAAP basis, Q3'22 net income was $106.5 million, or $1.36 per diluted share.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today introduced the latest release of the iTero-exocad Connector,™ which integrates iTero intraoral camera and NIRI images within exocad DentalCAD 3.1 Rijeka software.

Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report third quarter 2022 financial results on Wednesday, October 26, 2022, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry, today introduced Invisalign Virtual Care AI, its next generation remote monitoring solution with new artificial intelligence-assisted capabilities that streamline workflows for doctors and their staff. It includes features such as patient enrollment, setup, and review directly on the Invisalign Doctor Site without the need to use separate standalone solutions. Invisalign Virtual Care AI helps doctors remotely monitor Invisalign treatment progress based on their own pre-approved clinical settings and AI-assisted algorithms for Automatic Assessment calibrated to each doctor’s ClinCheck treatment features. AI-assisted Automated Notifications, based on doctor settings, guide patients to either advance to the next aligner stage if their treatment is tracking well or to stay on their current stage for longer or to contact their doctor if their treatment is not tracking.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM services for orthodontic and restorative dentistry, today announced the official opening of the first Europe, Middle East & Africa (EMEA) regional manufacturing facility in Wroclaw, Poland. The new plant is Align’s third regional manufacturing facility worldwide, after Juarez, Mexico and Ziyang, China.

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the second quarter of fiscal 2022 ("Q2'22"). Q2'22 total revenues were $969.6 million, down 0.4% sequentially and down 4.1% year-over-year. Q2'22 Clear Aligner revenues were $798.4 million, down 1.4% sequentially and down 5.1% year-over-year. Q2'22 Imaging Systems and CAD/CAM Services revenues were $171.2 million, up 4.7% sequentially and up 0.8% year-over-year. Q2'22 Clear Aligner volume was flat sequentially and down 10.0% year-over-year. Q2’22 Imaging Systems and CAD/CAM Services revenues were unfavorably impacted by foreign exchange of approximately $2.9 million or 1.7% sequentially and approximately $7.0 million or 3.9% year over year.(1) Q2’22 Clear Aligner revenues were unfavorably impacted by foreign exchange of approximately $12.3 million or 1.5% sequentially and approximately $32.9 million or 4.0% year over year.(1) Q2'22 operating income was $188.2 million resulting in an operating margin of 19.4%. Q2'22 net income was $112.8 million, or $1.44 per diluted share. On a non-GAAP basis, Q2'22 net income was $157.0 million or $2.00 per diluted share.

Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report second quarter 2022 financial results on Wednesday, July 27, 2022, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry today announced a $250 thousand donation to JA (Junior Achievement) Worldwide through the Align Foundation, the Company’s donor-advised charitable fund through Fidelity Charitable. The donation to JA commemorates Align’s 25th anniversary milestone as a company that has transformed smiles and changed lives for millions of people around the world through Align’s pioneering technology innovations and doctor-driven business model.

Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the award of eleven research grants to universities under the company’s twelfth Annual Research Award Program.